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STAGE A PROSTATE CANCER: COMPARISON OF 
SUBCLASSIFICATION BETWEEN jAPANESE RULE 
AND TNM， AND OUTCOME 
Masashi TANAKA， Noriyuki SUZUKI， Hiroomi NAKATSU， 
Shino MURAKAMI， Osamu MATSUZAKI and Jun SHIMAZAKI 
From the Dψartment 01 Urology， Asahi General Hospital 
Between 1980 and J une， 2002， transurethral resection of prostate was performed aginst 3294 cases 
ofbenign prostatic hyperplasia， and 144 cases ofstage A cancer were detected (4.4%). Among these 
cases， 136 cases which had complete records of examination were studied. Annual number of stage A 
and Al : A2 ratio were not influenced by introducing PSA determination from 1991， although the 
number of Tlc has been increasing gradually. Since subclassification of stage A is different between 
japanese rules (Al ; 3 chips of cancer with well-differentiated adenocarcinoma， A2 ; others) and TNM 
(Tla; 5% ofless number of chips with cancer， Tlb ; others)， two criteria were compared. Coincidence 
was found with 93.7%， and disagreement was due to ratio of number of chips with cancer to whole 
number resected， ordifferent grade. The former difference was caused by a larger or smaller prostate. 
Most cases of Al and A2 were subjected to watchful waiting or subsequent therapy. PSA was elevated 
in 10 cases (7%)， two of which died from progression of cancer. Other cases were disease-free. 
Individual pathological findings are important for subclassification of stage A 
(Acta Urol. Jpn. 49: 579-582， 2003) 

































的分化度の判明している 136例を対象とした. Stage 
Aの亜分類として， 3チップまでの高分化癌を Al，
それ以外を A2としたもの(日本分類)と，総チップ
14.7， 18.51: 14.9). 両群の G1easonscoreは A1が
3 (3.71:1.0)， A2が5 (4.8土1.4) で差をみた
(p<O.OOOl) . 











不一致9例 (6.6%) を Table2にしめす癌の
チップが3以上の高分化癌 (A2)であるが大きな前立
腺で総チップ数が多く，癌が5%以下のため Tlaが
5例 (3.7%，症例 1-5)，総チップ数の 5%以下の











例 74月，全摘 l例 9月)， A2， Tlaの l例 (81


















A1の患者年齢は71.0歳(中央値) (72.li:6.2， M 
土SD)，A2のそれは76.0(75.4土7.1)であり，間
群間に差をみとめた (p<O.01).切除重量は両群聞に


































Patients of AI are Tla except three cases (* : Tlb). 
Patients of A2 are Tlb except six cases け:Tla). 
7:3 45 91 Total 
Cases of different substages Table 2 
Outcome 
PSA↑6 y 9 m.later 
Death from other disease 
Surviving， 8 y Im 
Surviving， 8 y 4 m 
Surviving， 1 y 3 m 
Surviving， 2 y 6 m 
Surviving， 1 y 
Surviving， 9 m 



























































Ope: Total prostatectomy. 







7 ( 8%) 
13 (29%) 
Radiation 
1 ( 1%) 
17 (38%) 
Total prostaleclomy 




















' o 60 120 180 240 300 
months 
Overall survival rate. Number in 
parentheses is the number of cases. 
AITla vs A2Tlb; p<O.OO1. 








































Gleason score 2 -4のみとしたが，その後の検討で
5， 6もTlaに含めた14，15) また癌のチァプが5%
以下でも Gleasonscore 8以上は A2Tlbに含めると
提案された16) 新しい stagegroupingでは癌のチ、ソ
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